Patient-Reported OutcomesQuality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer’s Disease: Determinants and Level of Changes Observed☆
Under an Elsevier user license
open archive
Keywords
Alzheimer’s disease
Health Utility Index (HUI)
patient-reported outcomes
Quality of Life in Alzheimer’s Disease (QOL-AD)
Cited by (0)
- ☆
Conflict of interest: Loretto Lacey and Chris Leibman were full-time employees of Janssen Alzheimer Immunotherapy Research & Development, LLC, at the time the work was conducted. Joel Bobula, Katja Rüdell, and Jose Alvir are employees of Pfizer, Inc.
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.